8-(17-Carboxy-11-oxo-3,10-diazapentacyclo[10.7.1.02,10.04,9.016,20]icosa-1(19),2,4,6,8,12(20),13,15,17-nonaen-15-yl)naphthalene-1,4,5-tricarboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 8-(17-Carboxy-11-oxo-3,10-diazapentacyclo[10.7.1.02,10.04,9.016,20]icosa-1(19),2,4,6,8,12(20),13,15,17-nonaen-15-yl)naphthalene-1,4,5-tricarboxylic acid
• 化学式: C₃₂H₁₆N₂O₉
• 分子量: 572.5
• InChiKey: JTNWBGQUZKOYTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  43
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  184
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• [EN] INHIBITION OF CLATHRIN<br/>[FR] INHIBITION DE LA CLATHRINE
  申请人：UNIV BERLIN FREIE

  公开号：WO2013010218A9

  公开（公告）日：2013-03-28
• Methods and compositions for treating beta-thalassemia and sickle cell disease
  申请人：Academia Sinica

  公开号：EP2678339B1

  公开（公告）日：2016-07-13
• METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE
  申请人：Shen Che-Kun James

  公开号：US20140088133A1

  公开（公告）日：2014-03-27

  The present invention provides compounds (such as compounds of formula I-a) that induce γ globin expression and pharmaceutical compositions thereof. Such compounds may have beneficial therapeutic effects. Compounds and compositions described herein may be used to treat hemoglobinopathies such as β-thalassemia and sickle cell anemia. (I-a)
• US8822491B2
  申请人：——

  公开号：US8822491B2

  公开（公告）日：2014-09-02